EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cyclic RGD-Functionalized pH/ROS Dual-Responsive Nanoparticle for Targeted Breast Cancer Therapy

Pu Yao, Xiaowen Wang, Qianmei Wang, Qing Dai, Yu Peng, Qian Yuan, Nan Mou, Shan Lv, Bangbi Weng, Yu Wang, Fengjun Sun

Pharmaceutics · 26.06.2023 · 15 (7) · 1827

DOI: 10.3390/pharmaceutics15071827 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 26.06.2023. Verfasst von Pu Yao und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Southwest Hospital, Army Medical University (Third Military Medical University), Chongqing 400038, China. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Special Project of Common Key Technology Innovation for Key Industries in Chongqing.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Breast cancer is the most common malignant tumor in women and is a big challenge to clinical treatment due to the high morbidity and mortality. The pH/ROS dual-responsive nanoplatforms may be an effective way to significantly improve the therapeutic efficacy of breast cancer. Herein, we report a docetaxel (DTX)-loaded pH/ROS-responsive NP that could achieve active targeting of cancer cells and selective and complete drug release for effective drug delivery. The pH/ROS-responsive NPs were fabricated using nanocarriers that consist of an ROS-responsive moiety (4-hydroxymethylphenylboronic acid pinacol ester, HPAP), cinnamaldehyde (CA, an aldehyde organic compound with anticancer activities) and cyclodextrin (α-CD). The NPs were loaded with DTX, modified with a tumor-penetration peptide (circular RGD, cRGD) and named DTX/RGD NPs. The cRGD could promote DTX/RGD NPs penetration into deep tumor tissue and specifically target cancer cells. After internalization by cancer cells through receptor-mediated endocytosis, the pH-responsive acetal was cleaved to release CA in the lysosomal acidic environment. Meanwhile, the high ROS in tumor cells induced the disassembly of NPs with complete release of DTX. In vitro cellular assays verified that DTX/RGD NPs could be effectively internalized by 4T1 cells, obviously inducing apoptosis, blocking the cell cycle of 4T1 cells and consequently, killing tumor cells. In vivo animal experiments demonstrated that the NPs could target to the tumor sites and significantly inhibit the tumor growth in 4T1 breast cancer mice. Both in vitro and in vivo investigations demonstrated that DTX/RGD NPs could significantly improve the antitumor effect compared to free DTX. Thus, the DTX/RGD NPs provide a promising strategy for enhancing drug delivery and cancer therapy.

Schlagwörter

Stichwörter der Autor:innen

breast cancercRGDcancer therapydrug releasepH/ROS dual-responsive NPs

Autor:innen und Institutionen

  • Department of Pharmacy, Southwest Hospital, Army Medical University (Third Military Medical University), Chongqing 400038, China.
  • Department of Oncology, Southwest Hospital, Army Medical University (Third Military Medical University), Chongqing 400038, China.

Förderung

  • National Natural Science Foundation of China
  • Special Project of Common Key Technology Innovation for Key Industries in Chongqing

Zitieren

APA

Yao, P., Wang, X., Wang, Q., Dai, Q., Peng, Y., Yuan, Q., Mou, N., Lv, S., Weng, B., Wang, Y., & Sun, F. (2023). Cyclic RGD-Functionalized pH/ROS Dual-Responsive Nanoparticle for Targeted Breast Cancer Therapy. Pharmaceutics, 15(7), 1827. https://doi.org/10.3390/pharmaceutics15071827

Vancouver

Yao P, Wang X, Wang Q, Dai Q, Peng Y, Yuan Q, et al. Cyclic RGD-Functionalized pH/ROS Dual-Responsive Nanoparticle for Targeted Breast Cancer Therapy. Pharmaceutics. 2023;15(7):1827. doi:10.3390/pharmaceutics15071827

BibTeX
@article{Yao2023,
  author = {Yao, Pu and Wang, Xiaowen and Wang, Qianmei and Dai, Qing and Peng, Yu and Yuan, Qian and Mou, Nan and Lv, Shan and Weng, Bangbi and Wang, Yu and Sun, Fengjun},
  title = {Cyclic RGD-Functionalized pH/ROS Dual-Responsive Nanoparticle for Targeted Breast Cancer Therapy},
  journal = {Pharmaceutics},
  year = {2023},
  volume = {15},
  number = {7},
  pages = {1827},
  doi = {10.3390/pharmaceutics15071827}
}
Kostenlos starten →